Instrument Inactif

Autres langues DiaMedica Inc. Toronto S.E.

Actions

DMA

CA25253T1075

Recherche biotechnologique et médicale

Cours en clôture Toronto S.E. Autres places de cotation
- ^CAD	-

23/06	DiaMedica Therapeutics administre les premières doses à des patientes dans un essai de phase 2 de DM199 pour le traitement du retard de croissance fœtale	CI
23/06	DiaMedica Therapeutics administre les premières doses à des patients dans un essai de phase 2 sur le retard de croissance fœtale	MT

Autres langues

17/07	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/06	Diamedica Therapeutics Doses First Patients in Phase 2 Trial of DM199 for Treatment of Fetal Growth Restriction
23/06	DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial
23/06	DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
16/06	DiaMedica Therapeutics Inc. Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
16/06	DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements
16/06	DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
27/05	DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
20/05	DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment
20/05	Diamedica Therapeutics announces 75% enrollment milestone in Remedy2 phase 2/3 acute ischemic stroke trial
20/05	DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
20/05	DiaMedica Therapeutics Inc. Announces 75% Enrollment Milestone In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
12/05	DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
06/05	DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
30/04	DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
21/04	RedChip's Biotech Virtual Investor Conference Replays Now Available
07/04	RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
30/03	DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
30/03	DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
23/03	DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
05/03	Diamedica Therapeutics Inc Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
05/03	DiaMedica Says Health Canada Grants Regulatory Clearance to Begin Phase 2 Trial of DM199 for Preeclampsia
05/03	DiaMedica Therapeutics receives Health Canada clearance to initiate phase 2 study of DM199 in preeclampsia
05/03	DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia